HOME >> BIOLOGY >> NEWS
HPV testing a cost-effective strategy for women with equivocal cervical screening results

A new study has found that using human papillomavirus (HPV) DNA testing to determine who should receive a cervical examination called colposcopy is a cost-effective management strategy for women with equivocal Pap test results known as ASCUS (atypical squamous cells of undetermined significance). The study appears in the January 18 issue of the Journal of the National Cancer Institute.

About 5% of all Pap tests result in a diagnosis of ASCUS; however, only about 10% of women with this abnormality actually have precancer or cancer. The ASCUS and low-grade squamous intraepithelial lesions (LSIL) triage study (ALTS) was launched in the late 1990s to determine the best management strategy for women with these Pap test abnormalities that would both maximize the detection of clinically significant disease and reduce the need for unnecessary office visits and procedures. Results from ALTS, published in 2003, found that referring only those women with a positive HPV test to colposcopy was as effective at detecting cervical precancer or cancer as referring all women to colposcopy.

Shalini L. Kulasingam, Ph.D., of the Duke Center for Clinical Health Policy Research, and colleagues used data from 3488 women with ASCUS enrolled in ALTS to study the cost-effectiveness of three management strategies studied in ALTS--immediate colposcopy, HPV DNA testing, or conservative management with repeat Pap tests at 6-month intervals.

They found that the cost associated with HPV DNA testing was acceptable given the number of precancers and cancers found by this strategy. HPV DNA testing was less costly and detected more cases of precancer than immediately sending all women to receive colposcopy. The least costly strategy was a single repeat Pap test with referral to colposcopy for only those women with a high grade Pap test result; however, this option detected the fewest cases of precancer. The researchers conclude that HPV DNA testing for women with ASCUS
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
17-Jan-2006


Page: 1 2

Related biology news :

1. Modular leukemia drug shows promise in early testing
2. Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths
3. XDx to present recent success with AlloMap molecular expression testing
4. Potential genetic testing for substance abuse raises hope, concern
5. U-M team: Genetic testing sheds light on degenerative eye disease
6. Antiretroviral resistance testing in HIV infected patients improves health and saves costs
7. Professors to develop hand-held pathogen testing device
8. Animal testing alternative has ticks trembling at the knees
9. New research to cut animal testing
10. New method of testing eggs for abnormalities could solve problems of embryo freezing
11. HPV testing finds precancerous lesions at a higher rate than conventional pap smears

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... ... 21, 2017 , ... Vixiar Medical announced today that it ... to The LaunchPort™ Accelerator at the City Garage in Port Covington. The LaunchPort™, ... business services to its Residents. , Vixiar Medical recently closed a $1.5 ...
(Date:9/21/2017)... ... September 21, 2017 , ... Today, BioPharma Institute, a ... the addition of 5 new courses to its prospectus. These include the eagerly-awaited ... CFR Part 11 on Electronic Records and Electronic Signatures (Part 11 of Title ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... it has appointed Vishwas Paralkar to the role of chief scientific officer. In ... He will report to Cybrexa’s president and CEO, Per Hellsund. , “I was ...
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... From ... cell therapy succeeded after standard medicine failed. Many of these people had lost all ... Not Regression Free Download (pdf) , “Neil takes readers ...
Breaking Biology Technology:
Cached News: